Health Optimization Index
TB-500 (Thymosin Beta-4 Fragment)
- Nick’s assessment
- Favorable
- Research evidence
- C, mixed evidence
- Attention
- 8.1 / 100▼ Falling this week
BioHarmony score
TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
TB-500 (Thymosin Beta-4 Fragment) is a 7.5–8.0/10 fit for people considering recovery repair, injury recovery, wound healing, or corneal healing, with the strongest case in acute, well-defined repair problems rather than broad wellness use. The human anchors sit on full-length thymosin beta-4, not the injected fragment, and they read as a trend rather than a win: Sosne 2023 missed its neurotrophic keratopathy primary endpoint at p=0.0656 in a trial stopped early at 18 patients, Sosne 2015 missed its dry-eye primary endpoints with significant secondaries, and the confirmatory European Phase 3 later missed as well. That mixed clinical record, plus strong preclinical and community recovery signal, is why TB-500 scores as a strong but caveated repair experiment. Treat TB-500 (Thymosin Beta-4 Fragment) as a tracked trial: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Active adults with acute, well-defined tendon, ligament, muscle, or post-surgical recovery needs who already understand injectable peptide tradeoffs. TB-500 is most rational when conservative recovery is underway but too slow, when BPC-157 alone feels too narrow, and when the user can verify peptide quality. It is also worth tracking for people interested in full-length ophthalmic Tbeta4 research, where the human research is more direct than the musculoskeletal TB-500 story, even though its pivotal Phase 3 endpoints still missed. Pair it with progressive loading, protein, sleep, and clinician-aware recovery planning.
❌ Avoid if: You have active cancer, recent cancer, a strong family pattern of aggressive cancers, pregnancy, breastfeeding, or a WADA-tested sport context. Avoid TB-500 if you cannot verify source quality or sterile handling, because gray-market injection risk is separate from the molecule's theoretical profile. Avoid it if you need guideline-grade evidence before acting, because no large human musculoskeletal RCT exists. Also avoid using TB-500 to push through pain while ignoring diagnosis, imaging, surgical instructions, load management, or infection signs.
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →